Antengene Corporation Ltd
HKEX:6996
Net Margin
Antengene Corporation Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Antengene Corporation Ltd
HKEX:6996
|
1.9B HKD |
-347%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
710.9B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
368.5B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
200.6B CHF |
20%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.3B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
159.1B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.2B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
114.5B EUR |
13%
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Antengene Corporation Ltd's most recent financial statements, the company has Net Margin of -347.2%.
You don't have any saved screeners yet